Alnylam Pharmaceuticals (NASDAQ:ALNY) Earns Neutral Rating from Cantor Fitzgerald

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report)'s stock had its "neutral" rating restated by equities research analysts at Cantor Fitzgerald in a report released on Monday, Benzinga reports. They currently have a $220.00 target price on the biopharmaceutical company's stock. Cantor Fitzgerald's price objective indicates a potential downside of 13.10% from the stock's previous close.

Several other equities analysts have also recently weighed in on ALNY. Canaccord Genuity Group lifted their price target on Alnylam Pharmaceuticals from $357.00 to $366.00 and gave the company a "buy" rating in a research report on Friday, August 2nd. BMO Capital Markets reiterated an "outperform" rating and issued a $234.00 price target on shares of Alnylam Pharmaceuticals in a research report on Monday, June 24th. Citigroup lifted their price target on Alnylam Pharmaceuticals from $291.00 to $342.00 and gave the company a "buy" rating in a research report on Friday, August 2nd. Raymond James lifted their price target on Alnylam Pharmaceuticals from $242.00 to $275.00 and gave the company an "outperform" rating in a research report on Friday, August 2nd. Finally, Evercore ISI lifted their price target on Alnylam Pharmaceuticals from $210.00 to $260.00 and gave the company an "outperform" rating in a research report on Tuesday, June 25th. Seven equities research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $279.14.

Alnylam Pharmaceuticals Stock Performance

NASDAQ ALNY traded up $6.38 on Monday, hitting $253.16. 865,502 shares of the stock traded hands, compared to its average volume of 902,818. The business's fifty day moving average is $257.35 and its two-hundred day moving average is $191.53. Alnylam Pharmaceuticals has a 12 month low of $141.98 and a 12 month high of $287.55. The firm has a market capitalization of $32.50 billion, a price-to-earnings ratio of -94.92 and a beta of 0.38.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last announced its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.74) by $0.61. The firm had revenue of $659.83 million for the quarter, compared to the consensus estimate of $447.22 million. During the same period last year, the company posted ($2.21) earnings per share. Alnylam Pharmaceuticals's revenue for the quarter was up 107.0% on a year-over-year basis. Analysts expect that Alnylam Pharmaceuticals will post -2.78 EPS for the current fiscal year.

Insider Activity

In related news, CEO Yvonne Greenstreet sold 15,000 shares of the business's stock in a transaction dated Tuesday, August 20th. The stock was sold at an average price of $280.00, for a total transaction of $4,200,000.00. Following the transaction, the chief executive officer now owns 73,441 shares in the company, valued at approximately $20,563,480. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In related news, CEO Yvonne Greenstreet sold 15,000 shares of the business's stock in a transaction dated Tuesday, August 20th. The stock was sold at an average price of $280.00, for a total transaction of $4,200,000.00. Following the transaction, the chief executive officer now owns 73,441 shares in the company, valued at approximately $20,563,480. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director David E. I. Pyott sold 32,450 shares of the business's stock in a transaction dated Monday, June 24th. The shares were sold at an average price of $220.69, for a total value of $7,161,390.50. Following the transaction, the director now owns 136 shares in the company, valued at approximately $30,013.84. The disclosure for this sale can be found here. In the last quarter, insiders sold 103,148 shares of company stock valued at $25,658,824. Insiders own 1.50% of the company's stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Allspring Global Investments Holdings LLC grew its holdings in shares of Alnylam Pharmaceuticals by 572.0% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 168 shares of the biopharmaceutical company's stock worth $25,000 after acquiring an additional 143 shares during the period. Ashton Thomas Private Wealth LLC purchased a new position in shares of Alnylam Pharmaceuticals during the 2nd quarter worth approximately $26,000. Altitude Crest Partners Inc. purchased a new position in shares of Alnylam Pharmaceuticals during the 1st quarter worth approximately $30,000. Robeco Institutional Asset Management B.V. grew its holdings in shares of Alnylam Pharmaceuticals by 155.7% during the 4th quarter. Robeco Institutional Asset Management B.V. now owns 20,549 shares of the biopharmaceutical company's stock worth $39,000 after acquiring an additional 12,513 shares during the period. Finally, V Square Quantitative Management LLC purchased a new position in shares of Alnylam Pharmaceuticals during the 4th quarter worth approximately $52,000. Hedge funds and other institutional investors own 92.97% of the company's stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.